596 studies found for:    Open Studies | "Ovarian Diseases"
Show Display Options
Rank Status Study
21 Not yet recruiting ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Conditions: Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: Chemotherapy;   Drug: Rucaparib
22 Not yet recruiting Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Olaparib;   Drug: Cediranib;   Drug: Platinum-based Chemotherapy
23 Not yet recruiting Cost Utility of Radical Surgery in Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Other: Collection of additional data with questionnaires
24 Not yet recruiting Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Biological: Bevacizumab;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
25 Recruiting The Effect of Surgery for Non Endometriosic Ovarian Cysts on Ovarian Reserve
Conditions: Antimullerian Hormone;   Ovarian Cysts;   Antral Follicle Count
Intervention:
26 Recruiting Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer
Condition: Recurrent Ovarian Cancer
Interventions: Device: Cryosurgery;   Biological: NK immunotherapy
27 Not yet recruiting Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation Syndrome
Condition: Ovarian Hyperstimulation Syndrome
Interventions: Drug: bromocriptine;   Drug: dexamethasone
28 Not yet recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Atezolizumab;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment
29 Recruiting Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
Conditions: Renal Cell Carcinoma;   Colorectal Adenocarcinoma;   Non-squamous Non-small Cell Lung Cancer;   Platinum-refractory Ovarian Carcinoma;   Cervical Carcinoma
Interventions: Drug: Nintedanib;   Drug: Bevacizumab
30 Recruiting PerClot Compared to Usual Care in Gynaecology Procedures
Conditions: Endometriosis;   Ovarian Cyst;   Menorrhagia;   Cancer;   Uterine Fibroids
Interventions: Device: PerClot;   Device: Floseal, Surgicel, Surgiflo, Arista;   Procedure: Electrocautery/Diatermy
31 Not yet recruiting Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
Conditions: Fallopian Tube Carcinoma;   Peritoneal Carcinoma;   Epithelial Ovarian Cancer
Interventions: Drug: Pembrolizumab;   Drug: Paclitaxel;   Drug: Carboplatin
32 Not yet recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Conditions: Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bladder Adenocarcinoma;   Bronchioloalveolar Carcinoma;   Cervical Adenocarcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Endometrial Adenocarcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Skin Neoplasm;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
33 Not yet recruiting Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Recombinant NY-ESO-1 Protein;   Drug: Sirolimus
34 Recruiting Point of Care 3D Ultrasound for Various Applications: A Pilot Study
Conditions: Appendicitis;   Evidence of Cholecystectomy;   Gallstones;   Pregnancy, Ectopic;   Aortic Aneurysm;   Kidney Stones;   Intrauterine Pregnancy;   Diverticulitis;   Abdominal Injuries;   Tumors;   Pancreatitis;   Digestive System Diseases;   Gastrointestinal Diseases;   Intraabdominal Infections;   Intestinal Diseases;   Pregnancy;   Vascular Disease;   Uterine Fibroids;   Ovarian Cysts;   Uterine Abnominalies;   Bladder Abnominalies;   Testicular Abnominalies;   Polyps
Intervention:
35 Recruiting Trial on Radical Upfront Surgery in Advanced Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Procedure: PDS;   Drug: 6 cycles of standard chemotherapy;   Drug: 3 cycles of standard NACT;   Procedure: IDS;   Drug: 3 cycles of standard chemotherapy
36 Recruiting Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
Condition: Relapsed Ovarian Cancer
Intervention: Drug: trabectedin
37 Recruiting Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome
Condition: Infertility
Intervention: Drug: Cetrorelix
38 Not yet recruiting Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer
Condition: Ovarian Epithelial Cancer
Interventions: Drug: Olaparib;   Drug: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
39 Not yet recruiting Study of Azacitidine and Durvalumab in Advanced Solid Tumors
Conditions: Microsatellite Stable Colorectal Carcinoma;   Platinum Resistant Epithelial Ovarian Cancer Type II;   Estrogen Receptor Positive and HER2 Negative Breast Cancer
Interventions: Drug: Azacitidine;   Drug: Durvalumab
40 Not yet recruiting Improving Quality of Care for Patients With Recurrent Ovarian Cancer
Conditions: Ovarian Neoplasms;   Quality of Life
Intervention: Other: Questionnaires

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years